<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-06-22T07:57:45Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/931DB1E6-4903-474D-8A56-BA02281BF7D4" ns1:id="931DB1E6-4903-474D-8A56-BA02281BF7D4"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/persons/F76BB381-0A7C-42AC-A187-D55AB3E73D3B" ns1:rel="PM_PER"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/4A389749-5DBA-45D8-9552-AD14677FC123" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/4A389749-5DBA-45D8-9552-AD14677FC123" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/D9E2F69B-E694-49DC-B660-E0AA6C7A28E8" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2016-12-31T00:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/F18201AB-4F69-404F-95C6-573AE3AF8A20" ns1:rel="FUND" ns1:start="2014-09-30T23:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">101881</ns2:identifier></ns2:identifiers><ns2:title>The Virtual Patient Software</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Collaborative R&amp;D</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>The Virtual Patient Software is an industrial research project that will allow Aurora Medical Ltd to up-skill in order that they are ultimately in a position to offer a service to the orthopaedic community, whereby a statistical model of human joints will be utilised to predict implant outcomes. The proof of concept model already established at the University of Southampton will be developed so that this can support a significant reduction in the number of prototypes required during the development and clinical trial phases of new implant product market introduction, whilst improving the safety of those devices by accounting for the inherent variability in patients (including physiology and loading) and surgical factors. We anticipate that the costs of development to clinical trials can be reduced by 75%, with reduced timescales by 10%. By being able to account for some of the biomechanical factors that affect revision outcome (cases such as aseptic loosening, implant fracture, malignement and wear), in the longer term, the Virtual Patient Software will also have a significant impact on revision rates, and on the costs burden these represent on National Health Services.</ns2:abstractText></ns2:project>